Cargando…
Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence
Asthma is the commonest chronic disease affecting airways in humans and has an increasing global disease burden. Inhaled corticosteroids (ICS) are the first-line therapeutic option for asthma, and addition of a long-acting beta 2-agonist (LABA) has been shown to improve asthma control. A combination...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509561/ https://www.ncbi.nlm.nih.gov/pubmed/33005277 http://dx.doi.org/10.1155/2020/8631316 |
_version_ | 1783585623589781504 |
---|---|
author | Rajesh, V. Augustine, Jolsana Divya, R. Cleetus, Melcy |
author_facet | Rajesh, V. Augustine, Jolsana Divya, R. Cleetus, Melcy |
author_sort | Rajesh, V. |
collection | PubMed |
description | Asthma is the commonest chronic disease affecting airways in humans and has an increasing global disease burden. Inhaled corticosteroids (ICS) are the first-line therapeutic option for asthma, and addition of a long-acting beta 2-agonist (LABA) has been shown to improve asthma control. A combination of the two agents in a single inhaler is beneficial with regard to ease of administration and patient compliance. Various ICS-LABA formulations are available across various countries in the world, one among them being formoterol-fluticasone. Both formoterol and fluticasone have pharmacologic peculiarities which places the combination in a uniquely advantageous position when it comes to asthma therapy. The present review focuses on some of the, hitherto, less explored aspects of this combination inhaler such as real-world efficacy, impact on budget allocation, results of switch-over therapy, and potential to improve adherence to asthma treatment. It also provides practical recommendations on positioning it in real-world asthma management. |
format | Online Article Text |
id | pubmed-7509561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-75095612020-09-30 Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence Rajesh, V. Augustine, Jolsana Divya, R. Cleetus, Melcy Can Respir J Review Article Asthma is the commonest chronic disease affecting airways in humans and has an increasing global disease burden. Inhaled corticosteroids (ICS) are the first-line therapeutic option for asthma, and addition of a long-acting beta 2-agonist (LABA) has been shown to improve asthma control. A combination of the two agents in a single inhaler is beneficial with regard to ease of administration and patient compliance. Various ICS-LABA formulations are available across various countries in the world, one among them being formoterol-fluticasone. Both formoterol and fluticasone have pharmacologic peculiarities which places the combination in a uniquely advantageous position when it comes to asthma therapy. The present review focuses on some of the, hitherto, less explored aspects of this combination inhaler such as real-world efficacy, impact on budget allocation, results of switch-over therapy, and potential to improve adherence to asthma treatment. It also provides practical recommendations on positioning it in real-world asthma management. Hindawi 2020-09-14 /pmc/articles/PMC7509561/ /pubmed/33005277 http://dx.doi.org/10.1155/2020/8631316 Text en Copyright © 2020 V. Rajesh et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Rajesh, V. Augustine, Jolsana Divya, R. Cleetus, Melcy Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence |
title | Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence |
title_full | Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence |
title_fullStr | Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence |
title_full_unstemmed | Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence |
title_short | Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence |
title_sort | inhaled formoterol-fluticasone single inhaler therapy in asthma: real-world efficacy, budget impact, and potential to improve adherence |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509561/ https://www.ncbi.nlm.nih.gov/pubmed/33005277 http://dx.doi.org/10.1155/2020/8631316 |
work_keys_str_mv | AT rajeshv inhaledformoterolfluticasonesingleinhalertherapyinasthmarealworldefficacybudgetimpactandpotentialtoimproveadherence AT augustinejolsana inhaledformoterolfluticasonesingleinhalertherapyinasthmarealworldefficacybudgetimpactandpotentialtoimproveadherence AT divyar inhaledformoterolfluticasonesingleinhalertherapyinasthmarealworldefficacybudgetimpactandpotentialtoimproveadherence AT cleetusmelcy inhaledformoterolfluticasonesingleinhalertherapyinasthmarealworldefficacybudgetimpactandpotentialtoimproveadherence |